{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:32:27Z","timestamp":1787502747258,"version":"build-2736575974"},"reference-count":218,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australian Government Research Training Program (RTP)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Peripheral nerve disorders are caused by a range of different aetiologies. The range of causes include metabolic conditions such as diabetes, obesity and chronic kidney disease. Diabetic neuropathy may be associated with severe weakness and the loss of sensation, leading to gangrene and amputation in advanced cases. Recent studies have indicated a high prevalence of neuropathy in patients with chronic kidney disease, also known as uraemic neuropathy. Immune-mediated neuropathies including Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyradiculoneuropathy may cause significant physical disability. As survival rates continue to improve in cancer, the prevalence of treatment complications, such as chemotherapy-induced peripheral neuropathy, has also increased in treated patients and survivors. Notably, peripheral neuropathy associated with these conditions may be chronic and long-lasting, drastically affecting the quality of life of affected individuals, and leading to a large socioeconomic burden. This review article explores some of the major emerging clinical and experimental therapeutic agents that have been investigated for the treatment of peripheral neuropathy due to metabolic, toxic and immune aetiologies.<\/jats:p>","DOI":"10.3390\/ph15050607","type":"journal-article","created":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T09:48:22Z","timestamp":1652608102000},"page":"607","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6133-7411","authenticated-orcid":false,"given":"Jeremy Chung Bo","family":"Chiang","sequence":"first","affiliation":[{"name":"School of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria","family":"Arnold","sequence":"additional","affiliation":[{"name":"School of Medical, Indigenous and Health Science, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong 2500, Australia"},{"name":"School of Health Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Dhanapalaratnam","sequence":"additional","affiliation":[{"name":"Prince of Wales Clinical School, University of New South Wales, Sydney 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Markoulli","sequence":"additional","affiliation":[{"name":"School of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8883-8825","authenticated-orcid":false,"given":"Arun V.","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Prince of Wales Clinical School, University of New South Wales, Sydney 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_2","unstructured":"GBD Chronic Kidney Disease Collaboration (2020). Global, regional, and national burden of chronic kidney disease, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 395, 709\u2013733."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-019-0092-1","article-title":"Diabetic neuropathy","volume":"5","author":"Feldman","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/imj.14114","article-title":"Potassium control in chronic kidney disease: Implications for neuromuscular function","volume":"49","author":"Arnold","year":"2019","journal-title":"Intern. Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Timmins, H.C., Mizrahi, D., Li, T., Kiernan, M.C., Goldstein, D., and Park, S.B. (2021). Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: A systematic review. J. Cancer Surviv.","DOI":"10.1007\/s11764-021-00988-x"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Molassiotis, A., Cheng, H.L., Lopez, V., Au, J.S.K., Chan, A., Bandla, A., Leung, K.T., Li, Y.C., Wong, K.H., and Suen, L.K.P. (2019). Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5302-4"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00520-021-06502-4","article-title":"Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer","volume":"30","author":"Teng","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/ene.15204","article-title":"Increased mortality following Guillain-Barr\u00e9 syndrome: A population-based cohort study","volume":"29","author":"Levison","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000494291","article-title":"Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: A systematic review and meta-analysis","volume":"52","author":"Broers","year":"2019","journal-title":"Neuroepidemiology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12974-021-02319-4","article-title":"Global, regional, and national burden of Guillain-Barr\u00e9 syndrome and its underlying causes from 1990 to 2019","volume":"18","author":"Bragazzi","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/M20-1340","article-title":"Peripheral neuropathy and all-cause and cardiovascular mortality in U.S. adults: A prospective cohort study","volume":"174","author":"Hicks","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3122\/jabfm.17.5.309","article-title":"The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients","volume":"17","author":"Mold","year":"2004","journal-title":"J. Am. Board Fam. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"19159","DOI":"10.1038\/s41598-021-98565-w","article-title":"Prevalence of peripheral neuropathy defined by monofilament insensitivity in middle-aged and older adults in two US cohorts","volume":"11","author":"Hicks","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Formiga, F., Moreno-Gonz\u00e1lez, R., Corsonello, A., Carlsson, A., \u00c4rnl\u00f6v, J., Mattace-Raso, F., Kostka, T., Weingart, C., Roller-Wirnsberger, R., and Tap, L. (2022). Diabetes, sarcopenia and chronic kidney disease; the Screening for CKD among Older People across Europe (SCOPE) study. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-02916-9"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10522-018-9749-5","article-title":"A review of telomere length in sarcopenia and frailty","volume":"19","author":"Lorenzi","year":"2018","journal-title":"Biogerontology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Giovannini, S., Coraci, D., Brau, F., Galluzzo, V., Loreti, C., Caliandro, P., Padua, L., Maccauro, G., Biscotti, L., and Bernabei, R. (2021). Neuropathic pain in the elderly. Diagnostics, 11.","DOI":"10.3390\/diagnostics11040613"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: Prevalence, risk factors, and fall risk","volume":"159","author":"Bao","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diabres.2015.04.031","article-title":"Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: A review of the literature","volume":"109","author":"Alleman","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2040620719839025","DOI":"10.1177\/2040620719839025","article-title":"Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: A US administrative claims analysis","volume":"10","author":"Song","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1111\/ene.14805","article-title":"Impact of the metabolic syndrome on peripheral nerve structure and function in type 2 diabetes","volume":"28","author":"Issar","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1001\/jamaneurol.2016.3745","article-title":"Association between metabolic syndrome components and polyneuropathy in an obese population","volume":"73","author":"Callaghan","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1212\/WNL.43.4.817","article-title":"The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study","volume":"43","author":"Dyck","year":"1993","journal-title":"Neurology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nrneurol.2009.138","article-title":"Neurological complications of chronic kidney disease","volume":"5","author":"Krishnan","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2011.137","article-title":"Diabetic neuropathy: Cellular mechanisms as therapeutic targets","volume":"7","author":"Vincent","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/diacare.15.12.1902","article-title":"Complications: Neuropathy, pathogenetic considerations","volume":"15","author":"Greene","year":"1992","journal-title":"Diabetes Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.RES.81.3.363","article-title":"High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha","volume":"81","author":"Hempel","year":"1997","journal-title":"Circ. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jtos.2017.10.006","article-title":"The impact of diabetes on corneal nerve morphology and ocular surface integrity","volume":"16","author":"Markoulli","year":"2018","journal-title":"Ocul. Surf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00125-020-05085-9","article-title":"Diabetic neuropathy: What does the future hold?","volume":"63","author":"Callaghan","year":"2020","journal-title":"Diabetologia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.tips.2020.01.006","article-title":"Axons matter: The promise of treating neurodegenerative disorders by targeting SARM1-mediated axonal degeneration","volume":"41","author":"Krauss","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_32","first-page":"CD007543","article-title":"Enhanced glucose control for preventing and treating diabetic neuropathy","volume":"6","author":"Callaghan","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/jns.12387","article-title":"Evolving concepts on the role of dyslipidemia, bioenergetics, and inflammation in the pathogenesis and treatment of diabetic peripheral neuropathy","volume":"25","author":"Stino","year":"2020","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.neuron.2017.02.005","article-title":"New horizons in diabetic neuropathy: Mechanisms, bioenergetics, and pain","volume":"93","author":"Feldman","year":"2017","journal-title":"Neuron"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00125-019-4959-1","article-title":"New insights into the mechanisms of diabetic complications: Role of lipids and lipid metabolism","volume":"62","author":"Eid","year":"2019","journal-title":"Diabetologia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/B978-0-12-385506-0.00004-1","article-title":"Insulin, Synaptic Function, and Opportunities for Neuroprotection","volume":"98","author":"Mielke","year":"2011","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0006-8993(87)90704-9","article-title":"Insulin receptors in the peripheral nervous system: A structural and functional analysis","volume":"409","author":"Waldbillig","year":"1987","journal-title":"Brain Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neulet.2014.11.017","article-title":"Diabetes and the plasticity of sensory neurons","volume":"596","author":"Zochodne","year":"2015","journal-title":"Neurosci. Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/dc15-2068","article-title":"Long-acting C-peptide and neuropathy in Type 1 Diabetes: A 12-month clinical trial","volume":"39","author":"Wahren","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tem.2011.12.004","article-title":"Insulin resistance in the nervous system","volume":"23","author":"Kim","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: A report from an ADA consensus conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.clinph.2019.08.005","article-title":"Relative contributions of diabetes and chronic kidney disease to neuropathy development in diabetic nephropathy patients","volume":"130","author":"Issar","year":"2019","journal-title":"Clin. Neurophysiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/ndt\/gfab043","article-title":"Peripheral neuropathy: An important contributor to physical limitation and morbidity in stages 3 and 4 chronic kidney disease","volume":"37","author":"Arnold","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clinph.2013.06.022","article-title":"Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease","volume":"125","author":"Arnold","year":"2014","journal-title":"Clin. Neurophysiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.clinph.2016.09.010","article-title":"Haemodialysis alters peripheral nerve morphology in end-stage kidney disease","volume":"128","author":"Borire","year":"2017","journal-title":"Clin. Neurophysiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.clinph.2006.02.002","article-title":"Neuropathy, axonal Na+\/K+ pump function and activity-dependent excitability changes in end-stage kidney disease","volume":"117","author":"Krishnan","year":"2006","journal-title":"Clin. Neurophysiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2215\/CJN.00670117","article-title":"Randomized, controlled trial of the effect of dietary potassium restriction on nerve function in CKD","volume":"12","author":"Arnold","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/j.jcjd.2017.10.028","article-title":"Neuropathy","volume":"42","author":"Bril","year":"2018","journal-title":"Can. J. Diabetes"},{"key":"ref_49","first-page":"CD007115","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","volume":"1","author":"Lunn","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s11064-019-02736-1","article-title":"3-mercapto-5H-1,2,4-triazino[5,6-b]indole-5-acetic acid (Cemtirestat) alleviates symptoms of peripheral diabetic neuropathy in Zucker Diabetic Fatty (ZDF) rats: A role of aldose reductase","volume":"44","author":"Svik","year":"2019","journal-title":"Neurochem. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/jns.12138","article-title":"Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy","volume":"20","author":"Polydefkis","year":"2015","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/jdi.12890","article-title":"Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan","volume":"10","author":"Sekiguchi","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2337\/db10-1462","article-title":"Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice","volume":"60","author":"Himeno","year":"2011","journal-title":"Diabetes"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1463-1326.2011.01431.x","article-title":"GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice","volume":"13","author":"Jolivalt","year":"2011","journal-title":"Diabetes, Obes. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/j.1476-5381.2011.01272.x","article-title":"Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats","volume":"164","author":"Liu","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/NEN.0b013e3182580673","article-title":"Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy","volume":"71","author":"Kan","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1523\/JNEUROSCI.4703-13.2014","article-title":"Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity","volume":"34","author":"Gong","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_59","first-page":"2977","article-title":"GLP-1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK\/NF-\u03baB signaling pathways in streptozotocin-induced diabetic rats","volume":"41","author":"Ma","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"172835","DOI":"10.1016\/j.ejphar.2019.172835","article-title":"Therapeutic efficacy of arginine-rich exenatide on diabetic neuropathy in rats","volume":"866","author":"Shekunova","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/jnc.14336","article-title":"Liraglutide ameliorated peripheral neuropathy in diabetic rats: Involvement of oxidative stress, inflammation and extracellular matrix remodeling","volume":"146","author":"Moustafa","year":"2018","journal-title":"J. Neurochem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tem.2016.10.001","article-title":"Glucagon-like peptide-1 and the central\/peripheral nervous system: Crosstalk in diabetes","volume":"28","author":"Muscogiuri","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00125-019-4918-x","article-title":"Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes","volume":"62","author":"Aung","year":"2019","journal-title":"Diabetologia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/j.clinph.2021.05.033","article-title":"Effect of exenatide on peripheral nerve excitability in type 2 diabetes","volume":"132","author":"Issar","year":"2021","journal-title":"Clin. Neurophysiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jdiacomp.2015.07.013","article-title":"Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: Results from an 18-month proof-of-concept open-label randomized study","volume":"29","author":"Jaiswal","year":"2015","journal-title":"J. Diabetes Complicat."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10286-019-00607-x","article-title":"Physical activity and dietary interventions in diabetic neuropathy: A systematic review","volume":"29","author":"Zilliox","year":"2019","journal-title":"Clin. Auton. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2337\/dc16-1728","article-title":"Physical activity\/exercise and diabetes: A position statement of the American Diabetes Association","volume":"39","author":"Colberg","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e1077","DOI":"10.1016\/S2214-109X(18)30357-7","article-title":"Worldwide trends in insufficient physical activity from 2001 to 2016: A pooled analysis of 358 population-based surveys with 1.9 million participants","volume":"6","author":"Guthold","year":"2018","journal-title":"Lancet Glob. Health"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jdiacomp.2005.07.005","article-title":"Exercise training can modify the natural history of diabetic peripheral neuropathy","volume":"20","author":"Balducci","year":"2006","journal-title":"J. Diabetes Complicat."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Perrin, B.M., Southon, J., McCaig, J., Skinner, I., Skinner, T.C., and Kingsley, M.I.C. (2021). The effect of structured exercise compared with education on neuropathic signs and symptoms in people at risk of neuropathic diabetic foot ulcers: A randomized clinical trial. Medicina, 58.","DOI":"10.3390\/medicina58010059"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jdiacomp.2012.05.007","article-title":"The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy","volume":"26","author":"Kluding","year":"2012","journal-title":"J. Diabetes Complicat."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/acn3.125","article-title":"Exercise increases cutaneous nerve density in diabetic patients without neuropathy","volume":"1","author":"Singleton","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2337\/dc06-0224","article-title":"Lifestyle intervention for pre-diabetic neuropathy","volume":"29","author":"Smith","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ana.24310","article-title":"Supervised exercise improves cutaneous reinnervation capacity in metabolic syndrome patients","volume":"77","author":"Singleton","year":"2015","journal-title":"Ann. Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2522\/ptj.20160200","article-title":"Activity for Diabetic Polyneuropathy (ADAPT): Study design and protocol for a 2-site randomized controlled trial","volume":"97","author":"Kluding","year":"2017","journal-title":"Phys. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Skoglund, G., Nilsson, B.B., Olsen, C.F., Bergland, A., and Hilde, G. (2022). Facilitators and barriers for lifestyle change in people with prediabetes: A meta-synthesis of qualitative studies. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-12885-8"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1007\/s11695-019-04004-1","article-title":"The effect of bariatric surgery on peripheral polyneuropathy: A systematic review and meta-analysis","volume":"29","author":"Aghili","year":"2019","journal-title":"Obes. Surg."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7326\/M17-2383","article-title":"Microvascular outcomes in patients with diabetes after bariatric surgery versus usual care: A matched cohort study","volume":"169","author":"Johnson","year":"2018","journal-title":"Ann. Intern Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41366-020-00727-9","article-title":"Bariatric surgery leads to an improvement in small nerve fibre damage in subjects with obesity","volume":"45","author":"Azmi","year":"2021","journal-title":"Int. J. Obes."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11695-020-05052-8","article-title":"Improvements in diabetic neuropathy and nephropathy after bariatric surgery: A prospective cohort study","volume":"31","author":"Adam","year":"2021","journal-title":"Obes. Surg."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/oby.23246","article-title":"Dietary weight loss in people with severe obesity stabilizes neuropathy and improves symptomatology","volume":"29","author":"Callaghan","year":"2021","journal-title":"Obesity"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fbioe.2020.00490","article-title":"The construction and analysis of incRNA-miRNA-mRNA competing endogenous RNA network of Schwann cells in diabetic peripheral neuropathy","volume":"8","author":"Wang","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/j.pain.0000000000002159","article-title":"A genome-wide screen reveals microRNAs in peripheral sensory neurons driving painful diabetic neuropathy","volume":"162","author":"Bali","year":"2021","journal-title":"Pain"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuroscience.2016.05.005","article-title":"MicroRNA 146a locally mediates distal axonal growth of dorsal root ganglia neurons under high glucose and sildenafil conditions","volume":"329","author":"Jia","year":"2016","journal-title":"Neuroscience"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/DDDT.S157109","article-title":"Involvement of microRNA-146a in diabetic peripheral neuropathy through the regulation of inflammation","volume":"12","author":"Feng","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.2337\/db16-1182","article-title":"MicroRNA-146a mimics reduce the peripheral neuropathy in type 2 diabetic mice","volume":"66","author":"Liu","year":"2017","journal-title":"Diabetes"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"113694","DOI":"10.1016\/j.expneurol.2021.113694","article-title":"Treatment of diabetic peripheral neuropathy with engineered mesenchymal stromal cell-derived exosomes enriched with microRNA-146a provide amplified therapeutic efficacy","volume":"341","author":"Fan","year":"2021","journal-title":"Exp. Neurol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.nano.2019.01.007","article-title":"Nanoparticle-microRNA-146a-5p polyplexes ameliorate diabetic peripheral neuropathy by modulating inflammation and apoptosis","volume":"17","author":"Luo","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2337\/db19-0432","article-title":"Exosomes derived from Schwann cells ameliorate peripheral neuropathy in type 2 diabetic mice","volume":"69","author":"Wang","year":"2020","journal-title":"Diabetes"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00125-019-05043-0","article-title":"Mesenchymal stromal cell-derived exosomes ameliorate peripheral neuropathy in a mouse model of diabetes","volume":"63","author":"Fan","year":"2020","journal-title":"Diabetologia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000503325","article-title":"MicroRNA-193a downregulates HMGB1 to alleviate diabetic neuropathic pain in a mouse model","volume":"26","author":"Wu","year":"2019","journal-title":"Neuroimmunomodulation"},{"key":"ref_93","first-page":"587","article-title":"miR-590-3p alleviates diabetic peripheral neuropathic pain by targeting RAP1A and suppressing infiltration by the T cells","volume":"67","author":"Wu","year":"2020","journal-title":"Acta Biochim. Pol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"623","DOI":"10.17219\/acem\/131217","article-title":"Investigation of the role of miR-221 in diabetic peripheral neuropathy and related molecular mechanisms","volume":"30","author":"Wu","year":"2021","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00415-004-0323-5","article-title":"Immune mediated neuropathies--an update on therapeutic strategies","volume":"251","author":"Czaplinski","year":"2004","journal-title":"J. Neurol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(10)70041-7","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: Diagnostic and therapeutic challenges for a treatable condition","volume":"9","author":"Vallat","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.clinph.2013.03.025","article-title":"Nodo-paranodopathy: Beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies","volume":"124","author":"Uncini","year":"2013","journal-title":"Clin. Neurophysiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJM199511233332102","article-title":"Campylobacter jejuni infection and Guillain-Barr\u00e9 syndrome","volume":"333","author":"Rees","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1085-9489.2005.0010202.x","article-title":"The immunobiology of Guillain-Barre syndromes","volume":"10","author":"Willison","year":"2005","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: From pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp-2012-302312","article-title":"Biology of the blood\u2013nerve barrier and its alteration in immune mediated neuropathies","volume":"84","author":"Kanda","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2013Barr\u00e9 syndrome","volume":"326","author":"Schmitz","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): A randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/jnnp-2017-316427","article-title":"Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: A multicentre, open-label, 52-week phase III trial","volume":"88","author":"Kuwabara","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awab422","article-title":"Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy","volume":"145","author":"Cornblath","year":"2022","journal-title":"Brain"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1212\/WNL.42.3.506","article-title":"Multifocal demyelinating motor neuropathy: Cranial nerve involvement and immunoglobulin therapy","volume":"42","author":"Kaji","year":"1992","journal-title":"Neurology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0140-6736(92)93267-Q","article-title":"Intravenous immunoglobulin treatment in multifocal motor neuropathy","volume":"340","author":"Charles","year":"1992","journal-title":"Lancet"},{"key":"ref_109","first-page":"CD004429","article-title":"Intravenous immunoglobulin for multifocal motor neuropathy","volume":"1","author":"Vermeulen","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0065-2776(05)89002-9","article-title":"Negative signaling in Fc receptor complexes","volume":"89","author":"Lesourne","year":"2006","journal-title":"Adv. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ncprheum0481","article-title":"Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: Rationale and mechanisms of action","volume":"3","author":"Bayry","year":"2007","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Bril","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mus.20076","article-title":"Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system","volume":"30","author":"Kieseier","year":"2004","journal-title":"Muscle Nerve"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/jnnp-2014-310280","article-title":"Subcutaneous immunoglobulin in CIDP and MMN: A different long-term clinical response?","volume":"87","author":"Cocito","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jnnp-2013-307515","article-title":"Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP","volume":"86","author":"Cocito","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410110205","article-title":"Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment","volume":"11","author":"Dyck","year":"1982","journal-title":"Ann. Neurol."},{"key":"ref_117","first-page":"CD002062","article-title":"Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"11","author":"Hughes","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/archneur.65.11.1460","article-title":"Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids","volume":"65","author":"Muley","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"The Guillain-Barr\u00e9 Syndrome Study Group (1985). Plasmapheresis and acute Guillain-Barr\u00e9 syndrome. Neurology, 35, 1096\u20131104.","DOI":"10.1212\/WNL.35.8.1096"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"The French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome (1997). Appropriate number of plasma exchanges in Guillain-Barr\u00e9 syndrome. Ann. Neurol., 41, 298\u2013306.","DOI":"10.1002\/ana.410410304"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","article-title":"Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"314","author":"Dyck","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/mus.20524","article-title":"High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy","volume":"34","author":"Brannagan","year":"2006","journal-title":"Muscle Nerve"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.410300312","article-title":"Immunosuppressive treatment in multifocal motor neuropathy","volume":"30","author":"Feldman","year":"1991","journal-title":"Ann. Neurol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1212\/WNL.40.1.118","article-title":"A syndrome of asymmetric limb weakness with motor conduction block","volume":"40","author":"Krarup","year":"1990","journal-title":"Neurology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1085-9489.2005.10104.x","article-title":"High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy","volume":"10","author":"Gladstone","year":"2005","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1172\/JCI58743","article-title":"Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity","volume":"122","author":"Maurer","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"Viala","year":"2013","journal-title":"Neurology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1529-8027.2010.00270.x","article-title":"An open-label trial of rituximab (Rituxan\u00ae) in multifocal motor neuropathy","volume":"15","author":"Chaudhry","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.nmd.2009.04.013","article-title":"Beneficial effect of rituximab monotherapy in multifocal motor neuropathy","volume":"19","author":"Stieglbauer","year":"2009","journal-title":"Neuromuscul. Disord."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mus.10359","article-title":"Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies","volume":"27","author":"Renaud","year":"2003","journal-title":"Muscle Nerve"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1212\/NXI.0000000000000149","article-title":"Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins","volume":"2","author":"Querol","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jns.12194","article-title":"Inhibition of complement in Guillain-Barr\u00e9 syndrome: The ICA-GBS study","volume":"22","author":"Davidson","year":"2017","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","article-title":"Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model","volume":"131","author":"Halstead","year":"2008","journal-title":"Brain"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: A multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_136","first-page":"CD008630","article-title":"Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barr\u00e9 syndrome","volume":"1","author":"Doets","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.4049\/jimmunol.1401766","article-title":"Impaired dendritic cell function in a spontaneous autoimmune polyneuropathy","volume":"194","author":"Quan","year":"2015","journal-title":"J. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Meyer zu H\u00f6rste, G., Mausberg, A.K., M\u00fcller, J.I., Lehmann, H.C., L\u00f6ber, S., Gmeiner, P., Hartung, H.-P., St\u00fcve, O., Korth, C., and Kieseier, B.C. (2011). Quinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II molecules. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021223"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"12518","DOI":"10.1038\/s41598-017-12744-2","article-title":"Schwann cells promote post-traumatic nerve inflammation and neuropathic pain through MHC class II","volume":"7","author":"Hartlehnert","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12974-020-01821-5","article-title":"Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cells","volume":"17","author":"Blusch","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/1535-7163.MCT-19-0133","article-title":"Oxaliplatin\u2013DNA adducts as predictive biomarkers of FOLFOX response in colorectal cancer: A potential treatment optimization strategy","volume":"19","author":"Zimmermann","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1111\/jns.12336","article-title":"Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment","volume":"24","author":"Tamburin","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1111\/jns.12334","article-title":"Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment","volume":"24","author":"Islam","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neuro.2016.05.004","article-title":"Inhibition of the neuronal NF\u03baB pathway attenuates bortezomib-induced neuropathy in a mouse model","volume":"55","author":"Bruna","year":"2016","journal-title":"NeuroToxicology"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Leo, M., Schmitt, L.-I., K\u00fcsterarent, P., Kutritz, A., Rassaf, T., Kleinschnitz, C., Hendgen-Cotta, U.B., and Hagenacker, T. (2020). Platinum-based drugs cause mitochondrial dysfunction in cultured dorsal root ganglion neurons. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228636"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"101502","DOI":"10.1016\/j.redox.2020.101502","article-title":"Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib","volume":"32","author":"Jannuzzi","year":"2020","journal-title":"Redox Biol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1744806919840098","DOI":"10.1177\/1744806919840098","article-title":"Peripheral and central oxidative stress in chemotherapy-induced neuropathic pain","volume":"15","author":"Shim","year":"2019","journal-title":"Mol. Pain"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1038\/s41598-017-05784-1","article-title":"Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms","volume":"7","author":"Imai","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/10799893.2019.1655050","article-title":"Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma","volume":"39","author":"Sun","year":"2019","journal-title":"J. Recept. Signal Transduct."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s13577-019-00238-4","article-title":"Evodiamine ameliorates paclitaxel-induced neuropathic pain by inhibiting inflammation and maintaining mitochondrial anti-oxidant functions","volume":"32","author":"Wu","year":"2019","journal-title":"Hum. Cell"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1007\/s12035-019-1616-0","article-title":"Losartan, an angiotensin II type 1 receptor antagonist, alleviates mechanical hyperalgesia in a rat model of chemotherapy-induced neuropathic pain by inhibiting inflammatory cytokines in the dorsal root ganglia","volume":"56","author":"Kim","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/01480545.2018.1547739","article-title":"Protective effect of gastrodin on peripheral neuropathy induced by anti-tumor treatment with vincristine in rat models","volume":"44","author":"Qin","year":"2021","journal-title":"Drug Chem. Toxicol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"22884","DOI":"10.1038\/s41598-021-02439-0","article-title":"Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel","volume":"11","author":"Chiang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00520-020-05591-x","article-title":"Neu-horizons: Neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy\u2014A randomised controlled trial","volume":"29","author":"Trinh","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"107905","DOI":"10.1016\/j.neuropharm.2019.107905","article-title":"Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity","volume":"164","author":"Alberti","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1152\/jn.00260.2020","article-title":"Acute changes in nerve excitability following oxaliplatin treatment in mice","volume":"124","author":"Makker","year":"2020","journal-title":"J. Neurophysiol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1523\/JNEUROSCI.0899-17.2017","article-title":"DRG Voltage-gated sodium channel 1.7 is upregulated in paclitaxel-induced neuropathy in rats and in humans with neuropathic pain","volume":"38","author":"Li","year":"2017","journal-title":"J. Neurosci."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/brain\/awaa208","article-title":"Sodium channel Nav1.6 in sensory neurons contributes to vincristine-induced allodynia","volume":"143","author":"Chen","year":"2020","journal-title":"Brain"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.npep.2017.12.002","article-title":"Oxaliplatin-induced changes in expression of transient receptor potential channels in the dorsal root ganglion as a neuropathic mechanism for cold hypersensitivity","volume":"67","author":"Chukyo","year":"2018","journal-title":"Neuropeptides"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"136512","DOI":"10.1016\/j.neulet.2022.136512","article-title":"Participation of transient receptor potential vanilloid 1 in the analgesic effect of duloxetine for paclitaxel induced peripheral neuropathic pain","volume":"773","author":"Wang","year":"2022","journal-title":"Neurosci. Lett."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jphs.2017.03.004","article-title":"Vincristine-induced peripheral neuropathic pain and expression of transient receptor potential vanilloid 1 in rat","volume":"133","author":"Chiba","year":"2017","journal-title":"J. Pharmacol. Sci."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3389\/fphar.2019.00365","article-title":"Duloxetine, a balanced serotonin-norepinephrine reuptake inhibitor, improves painful chemotherapy-induced peripheral neuropathy by inhibiting activation of p38 MAPK and NF-\u03baB","volume":"10","author":"Meng","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40261-019-00882-6","article-title":"Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: A randomized controlled trial","volume":"40","author":"Salehifar","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CAD.0000000000001005","article-title":"Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: A real world, open-label experience","volume":"32","author":"Velasco","year":"2021","journal-title":"Anti-Cancer Drugs"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1111\/ajco.12822","article-title":"Efficacy and safety of oxycodone\/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea","volume":"14","author":"Kim","year":"2018","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/pmr.2020.0031","article-title":"Tramadol\/acetaminophen combination tablets in cancer patients with chemotherapy-induced peripheral neuropathy: A single-arm phase II study","volume":"1","author":"Naruge","year":"2020","journal-title":"Palliat. Med. Rep."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e18653","DOI":"10.1097\/MD.0000000000018653","article-title":"Effect of serotonin-norepinephrine reuptake inhibitors for patients with chemotherapy-induced painful peripheral neuropathy: A meta-analysis","volume":"99","author":"Song","year":"2020","journal-title":"Medicine"},{"key":"ref_171","first-page":"1154-e105","article-title":"Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: A randomized, double-blind trial","volume":"22","author":"Galhardoni","year":"2017","journal-title":"Oncologist"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/j.pain.0000000000001577","article-title":"Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: A randomized, placebo-controlled, crossover study","volume":"160","author":"Hincker","year":"2019","journal-title":"Pain"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00384-018-3104-9","article-title":"Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: Randomized, controlled study","volume":"33","author":"Ibrahim","year":"2018","journal-title":"Int. J. Color. Dis."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1089\/jpm.2018.0572","article-title":"Poly (ADP-ribose) polymerase inhibition for chemotherapy-induced peripheral neuropathy: A meta-analysis of placebo-controlled trials","volume":"22","author":"Balko","year":"2019","journal-title":"J. Palliat. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00520-017-4028-6","article-title":"Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis","volume":"26","author":"Kuriyama","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000515620","article-title":"Protective effects of vitamin E on chemotherapy-induced peripheral neuropathy: A meta-analysis of randomized controlled trials","volume":"77","author":"Miao","year":"2021","journal-title":"Ann. Nutr. Metab."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Wu, S., Bai, X., Guo, C., Huang, Z., Ouyang, H., Huang, J., and Zeng, W. (2021). Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: A meta-analysis with trial sequential analysis. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08884-4"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000445977","article-title":"Calcium and magnesium infusions for the prevention of oxaliplatin-induced peripheral neurotoxicity: A systematic review","volume":"90","author":"Jordan","year":"2016","journal-title":"Oncology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jnci\/djx259","article-title":"Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715)","volume":"110","author":"Hershman","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1038\/ncomms3501","article-title":"Species differences and molecular determinant of TRPA1 cold sensitivity","volume":"4","author":"Chen","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Gadgil, S., Erg\u00fcn, M., van den Heuvel, S.A., van der Wal, S.E., Scheffer, G.J., and Hooijmans, C.R. (2019). A systematic summary and comparison of animal models for chemotherapy induced (peripheral) neuropathy (CIPN). PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0221787"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1053\/j.seminoncol.2021.09.004","article-title":"Chemotherapy-induced peripheral neuropathy and rehabilitation: A review","volume":"48","author":"Zhang","year":"2021","journal-title":"Semin. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/14656566.2017.1415326","article-title":"Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity","volume":"19","author":"Cavaletti","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1570159X15666170915143217","article-title":"Prevention and treatment for chemotherapy-induced peripheral neuropathy: Therapies based on CIPN mechanisms","volume":"17","author":"Hu","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"763229","DOI":"10.3389\/fonc.2021.763229","article-title":"A Systematic review and meta-analysis of the effectiveness of neuroprotectants for paclitaxel-induced peripheral neuropathy","volume":"11","author":"Leen","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Szklener, K., Szklener, S., Michalski, A., \u017bak, K., Kury\u0142o, W., Rejdak, K., and Ma\u0144dziuk, S. (2022). Dietary supplements in chemotherapy-induced peripheral neuropathy: A new hope?. Nutrients, 14.","DOI":"10.3390\/nu14030625"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"703532","DOI":"10.3389\/fmolb.2021.703532","article-title":"A novel NAD signaling mechanism in axon degeneration and its relationship to innate immunity","volume":"8","author":"Hopkins","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41583-020-0269-3","article-title":"Programmed axon degeneration: From mouse to mechanism to medicine","volume":"21","author":"Coleman","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s42003-020-0776-9","article-title":"Systemic loss of Sarm1 protects Schwann cells from chemotoxicity by delaying axon degeneration","volume":"3","author":"Tian","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/hmg\/ddy356","article-title":"Low levels of NMNAT2 compromise axon development and survival","volume":"28","author":"Gilley","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e202106080","DOI":"10.1083\/jcb.202106080","article-title":"Sarm1 activation produces cADPR to increase intra-axonal Ca++ and promote axon degeneration in PIPN","volume":"221","author":"Li","year":"2022","journal-title":"J. Cell Biol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"113607","DOI":"10.1016\/j.expneurol.2021.113607","article-title":"Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in Sarm1\u2212\/\u2212 mice","volume":"338","author":"Gould","year":"2021","journal-title":"Exp. Neurol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1093\/brain\/awab184","article-title":"Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy","volume":"144","author":"Bosanac","year":"2021","journal-title":"Brain"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jns.12219","article-title":"Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy","volume":"22","author":"Turkiew","year":"2017","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"113636","DOI":"10.1016\/j.expneurol.2021.113636","article-title":"SARM1 is required in human derived sensory neurons for injury-induced and neurotoxic axon degeneration","volume":"339","author":"Chen","year":"2021","journal-title":"Exp. Neurol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/db18-1233","article-title":"Sarm1 gene deficiency attenuates diabetic peripheral neuropathy in mice","volume":"68","author":"Cheng","year":"2019","journal-title":"Diabetes"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e29626","DOI":"10.7554\/eLife.29626","article-title":"Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy","volume":"6","author":"Lococo","year":"2017","journal-title":"eLife"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"dmm032938","DOI":"10.1242\/dmm.032938","article-title":"Nmnat mitigates sensory dysfunction in a Drosophila model of paclitaxel-induced peripheral neuropathy","volume":"11","author":"Brazill","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"10654","DOI":"10.1073\/pnas.1809392115","article-title":"Pharmacological bypass of NAD+ salvage pathway protects neurons from chemotherapy-induced degeneration","volume":"115","author":"Liu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1167\/iovs.63.1.38","article-title":"Nicotinamide riboside alleviates corneal and somatic hypersensitivity induced by paclitaxel in male rats","volume":"63","author":"Hamity","year":"2022","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Zou, S., and Kumar, U. (2018). Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030833"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/fcp.12008","article-title":"The role of endocannabinoids in pain modulation","volume":"27","author":"Zogopoulos","year":"2013","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"110456","DOI":"10.1016\/j.biopha.2020.110456","article-title":"Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain","volume":"129","author":"Thomas","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1523\/JNEUROSCI.0403-12.2012","article-title":"Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy","volume":"32","author":"Khasabova","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/jpet.117.245704","article-title":"Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy","volume":"366","author":"Curry","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1124\/jpet.118.252288","article-title":"Brain-permeant and -impermeant inhibitors of fatty acid amide hydrolase synergize with the opioid analgesic morphine to suppress chemotherapy-induced neuropathic nociception without enhancing effects of morphine on gastrointestinal transit","volume":"367","author":"Slivicki","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bmcl.2018.11.048","article-title":"Discovery and evaluation of novel FAAH inhibitors in neuropathic pain model","volume":"29","author":"Bhuniya","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1021\/acsptsci.9b00008","article-title":"Targeting cannabinoid 1 and delta opioid receptor heteromers alleviates chemotherapy-induced neuropathic pain","volume":"2","author":"Sierra","year":"2019","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuropharm.2017.07.015","article-title":"Antiallodynic effect of \u03b2-caryophyllene on paclitaxel-induced peripheral neuropathy in mice","volume":"125","author":"Segat","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"173544","DOI":"10.1016\/j.ejphar.2020.173544","article-title":"The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence","volume":"886","author":"Iyer","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/mol.118.113233","article-title":"Cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal","volume":"95","author":"Li","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jpain.2018.10.007","article-title":"Cannabinoid type 2 receptor system modulates paclitaxel-induced microglial dysregulation and central sensitization in rats","volume":"20","author":"Wu","year":"2019","journal-title":"J. Pain"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1111\/bph.13887","article-title":"Single and combined effects of \u03949-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain","volume":"174","author":"King","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bph.12439","article-title":"Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy","volume":"171","author":"Ward","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s12031-019-01321-z","article-title":"Knockdown siRNA Targeting the mitochondrial sodium-calcium exchanger-1 inhibits the protective effects of two cannabinoids against acute paclitaxel toxicity","volume":"68","author":"Brenneman","year":"2019","journal-title":"J. Mol. Neurosci."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpainsymman.2013.02.018","article-title":"A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain","volume":"47","author":"Lynch","year":"2014","journal-title":"J. Pain Symptom Manag."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1758835921990203","DOI":"10.1177\/1758835921990203","article-title":"Effect of cannabis on oxaliplatin-induced peripheral neuropathy among oncology patients: A retrospective analysis","volume":"13","author":"Waissengrin","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"e12073","DOI":"10.1002\/jev2.12073","article-title":"Small extracellular vesicles ameliorate peripheral neuropathy and enhance chemotherapy of oxaliplatin on ovarian cancer","volume":"10","author":"Zhang","year":"2021","journal-title":"J. Extracell. Vesicles"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/5\/607\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:10:59Z","timestamp":1760137859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/5\/607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,15]]},"references-count":218,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ph15050607"],"URL":"https:\/\/doi.org\/10.3390\/ph15050607","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,15]]}}}